Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops the SSi Mantra surgical robotic system and SSi Mudra surgical instruments. Company news frequently highlights progress toward its stated goal of making robotic surgery more affordable and accessible to a larger segment of the global population.
News updates for SSII often cover developments related to the SSi Mantra platform, including new installations, clinical milestones, and telesurgery achievements. The company has reported thousands of surgical procedures performed using the SSi Mantra, including cardiac procedures and telesurgeries across categories such as pediatric, urology, gynecology, oncology, and general surgery. Announcements have also described the introduction of smaller 5-millimeter instruments designed for pediatric, cardiac, and head and neck surgery, as well as the use of the SSi Mantra Tele Surgeon Console for remote procedures.
Investors and healthcare professionals following SS Innovations can expect news on quarterly and annual financial results, including revenue from system sales, instrument sales, warranty sales, and lease income. Regulatory and clinical updates are another recurring theme, such as the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for multiple specialty indications.
This news feed aggregates press releases, SEC-related announcements, and other public communications from SS Innovations. It provides a single location to review updates on product developments, clinical experience, regulatory milestones, and corporate events related to SSII and its surgical robotic technologies.
SS Innovations (NASDAQ:SSII) has achieved a significant milestone by installing over 100 SSi Mantra surgical robotic systems across India and six other countries. The company reported that more than 5,000 surgical procedures have been completed using the system, including 240 cardiac surgeries and 32 telesurgeries, showing substantial growth from the 2,759 total procedures reported as of December 31, 2024.
The company plans to submit a De Novo application to the FDA by July 2025 for multiple indications and is pursuing European Union CE marking certification, expected by late 2025. SS Innovations aims to democratize robotic surgery access by expanding both in existing markets and new geographies.
SS Innovations (NASDAQ:SSII) has achieved a groundbreaking milestone by completing the world's first robotic telesurgery for weight loss using their SSi Mantra 3 surgical robotic system. The surgery was performed by Dr. Mohit Bhandari from a distance of 560 miles, connecting SS Innovations' headquarters in Gurugram to Mohak Bariatric & Robotic Surgery Centre in Indore, India.
Two One-Anastomosis Gastric Bypass (OAGB) procedures were successfully executed with zero perceptible lag and flawless precision. The achievement demonstrates the system's capability to deliver advanced surgical care to remote locations, potentially revolutionizing healthcare accessibility and affordability globally.
SS Innovations (NASDAQ: SSII) has achieved a significant milestone with its SSi Mantra surgical robotic system, successfully completing over 4,000 robotic surgeries across more than 100 types of procedures with zero complications. Notable achievements include 215 cardiac surgical procedures, with six performed via telesurgery across India using the SSi Mantra 3 system.
The system is currently approved in seven countries including India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine. The company is pursuing market expansion with expected European Union CE Mark decision by late 2025 and FDA approval targeted for first half of 2026. The SSi Mantra system supports various surgical specialties including general surgery, urology, gynecology, cardiac, gastrointestinal, thoracic, head and neck, and breast and plastic procedures.
SS Innovations International (NASDAQ: SSII) announced plans to submit a De Novo Classification Request to the FDA for its SSi Mantra 3 surgical robotic system in July 2025. The company has demonstrated significant market traction with 80 SSi Mantra systems installed across 75 hospitals since August 2022, facilitating over 3,800 surgeries. The newer SSi Mantra 3 version, launched in June 2024, has 37 installations and has been used in more than 750 procedures, including 70 cardiac cases, with no device-related complications.
The FDA submission will seek approval for multiple surgical specialties including urology, gynecology, general surgery, and thoracic and cardiac surgery. The system is currently approved in six countries, and the company is simultaneously pursuing EU CE Mark approval.
SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, has announced a planned CFO transition. Arvind Palaniappan has been appointed as Interim CFO effective May 1, 2025, replacing Anup Sethi, who served as CFO during the company's growth phase. Under Sethi's seven-year tenure, the company successfully launched over 80 surgical robotic systems in India and internationally, and recently achieved a milestone with its Nasdaq uplisting on April 25. The company has initiated a search for a permanent CFO, while Sethi will remain available in an advisory capacity during the transition period.
SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:
Key highlights include:
- Installation of 80 systems across 75 hospitals in India and other countries
- 3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
- First Indian company to receive CDSCO approval for telesurgery
- Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles
The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.